ADAG | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

-3.83%

1 Month

27.36%

3 Months

110.61%

6 Months

87.10%

1 Year

142.44%

2 Year

34.64%

Key data

Stock price

$3.77

P/E Ratio

0.00

DAY RANGE

$3.62 - $4.14

EPS

N/A

52 WEEK RANGE

$1.30 - $4.58

52 WEEK CHANGE

$148.03

MARKET CAP

83.538 M

YIELD

N/A

SHARES OUTSTANDING

44.271 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-24-2025

BETA

1.13

PUBLIC FLOAT

AVERAGE 10 VOLUME

$131,166

AVERAGE 30 VOLUME

$244,710

Company detail

CEO: Pei Z. Luo
Region: US
Website: adagene.com
Employees: 260
IPO year: 2021

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 mAb that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma.

ADAG - Adagene Inc.